The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies

Abstract

The JN.1 variant of COVID-19 has emerged as the dominant strain worldwide since the end of 2023. As a subclade of the BA.2.86 variant, JN.1 harbors a unique combination of mutations inherited from the BA.2.86 lineage, notably featuring the novel L455S mutation within its receptor-binding motif. This mutation has been linked to increased transmissibility and enhanced immune evasion capabilities. During the rise of JN.1, evidence of resistance to various monoclonal antibodies and reduced cross-neutralization effects of the XBB.1.5 vaccine have been observed. Although the public health threat posed by the JN.1 variant appears relatively low, concerns persist regarding its evolutionary trajectory under immune pressure. This review provides a comprehensive overview of the evolving JN.1 variant, highlighting the need for continuous monitoring and investigation of new variants that could lead to widespread infection. It assesses the efficacy of current vaccines and therapeutics against emerging variants, particularly focusing on immunocompromised populations. Additionally, this review summarizes potential vaccine advancements and clinical treatments for COVID-19, offering insights to optimize prevention and treatment strategies. This review thoroughly evaluates the JN.1 variant’s impact on public health and its implications for future vaccine and therapeutic development, contributing to ongoing efforts to mitigate the risk of virus transmission and disease severity.

Keywords

immune evasion / JN.1 variant / response strategies / vaccine

References

[1] Tali SHS, LeBlanc JJ, Sadiq Z, et al. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 2021; 34(3):e00228-20.

[2] World Health Organization. WHO COVID-19 Dashboard. WHO Health Emergencies Programme. 2024. Accessed May 25, 2024. https://data.who.int/dashboards/covid19/cases?n=o

[3] World Health Organization. Statement on the Fifteenth Meeting of the IHR (2005). Emergency Committee on the COVID-19 Pandemic. WHO News. May 5, 2024. Accessed May 24, 2024. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic

[4] Ramesh S, Govindarajulu M, Parise RS, et al. Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy. Vaccines (Basel). 2021; 9(10): 1195.

[5] European Centre for Disease Prevention and Control. Risk Assessment: Risk Related to the Spread of New SARS-CoV-2 Variants of Concern in the EU/EEA. 2021. Accessed March 15, 2024. https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update

[6] Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations. Front Immunol. 2022; 13: 801522.

[7] World Health Organization. Tracking SARS-CoV-2 Variants. WHO Activities. 2024. Accessed March 15, 2024. https://www.who.int/activities/tracking-SARS-CoV-2-variants/

[8] Wang X, Lu L, Jiang S. SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread. Signal Transduct Target Ther. 2023; 8(1): 439.

[9] World Health Organization. COVID-19 Epidemiological Update—17 May 2024. Epidemic and Pandemic Preparedness and Prevention. May 17, 2024. Accessed May 25, 2024, https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-167

[10] Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect Dis. 2024; 24(2): e82.

[11] Yang S, Yu Y, Xu Y, et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect Dis. 2024; 24(2): e70-e72.

[12] Yang S, Yu Y, Jian F, et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Dis. 2023; 23(11): e457-e459.

[13] Planas D, Staropoli I, Michel V, et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. bioRxiv. 2024.

[14] Yang S, Yu Y, Jian F, et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Diseases. 2023; 23(11): e457-e459.

[15] Wang Q, Guo Y, Liu L, et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023; 624(7992): 639-644.

[16] Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2023; 614(7948): 521-529.

[17] GISAID. Tracking of hCoV-19 Variants. August 25, 2023. Accessed February 27, 2024. https://gisaid.org/hcov19-variants/

[18] Lodhi A. New COVID Strain JN.1 is Spreading Fast. How Worried Should We Be? Al Jazeera Media Network. December 22, 2023. Accessed March 29, 2024. https://www.aljazeera.com/news/2023/12/22/new-jn-1-covid-variant-how-worried-should-we-be

[19] Rosen A, Hartman M. What to Know About JN.1, the Latest Omicron Variant. Johns Hopkins, Bloomberg School of Public Health. January 9, 2024. Accessed March 24, 2024. https://publichealth.jhu.edu/2024/jn1-the-dominant-variant-in-the-covid-surge

[20] Centers for Disease Control and Prevention. Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC. National Center for Immunization and Respiratory Diseases. December 8, 2023. Accessed March 15, 2024. https://www.cdc.gov/ncird/whats-new/SARS-CoV-2-variant-JN.1.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Frespiratory-viruses%2Fwhats-new%2FSARS-CoV-2-variant-JN.1.html

[21] Harris E. CDC assesses risk from BA.2.86, highly mutated COVID-19 variant. JAMA. 2023; 330(11): 1029.

[22] Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020; 588(7837): 315-320.

[23] Pawelec G, Bronikowski A, Cunnane SC, et al. The conundrum of human immune system “senescence”. Mech Ageing Dev. 2020; 192: 111357.

[24] Centers for Disease Control and Prevention. Urgent Need to Increase Immunization Coverage for Influenza, COVID-19, and RSV and Use of Authorized/Approved Therapeutics in the Setting of Increased Respiratory Disease Activity During the 2023–2024 Winter Season. Emergency Preparedness and Response. December 14, 2023. Accessed March 26, 2024. https://emergency.cdc.gov/han/2023/han00503.asp

[25] Meo SA, Meo AS, Klonoff DC. Omicron new variant BA.2.86 (Pirola): epidemiological, biological, and clinical characteristics—a global data-based analysis. Eur Rev Med Pharmacol Sci. 2023; 27(19): 9470-9476.

[26] World Health Organization. IRE Clean—World Health Organization (WHO). WHO Activities. December 19, 2023. Accessed March 29, 2024. https://www.who.int/zh/activities/tracking-SARS-CoV-2-variants

[27] He Q, Wu L, Xu Z, et al. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB. Cell Rep Med. 2023; 4(4): 100991.

[28] Chen Q, Du P, Han Y, et al. Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine. Biosaf Health. 2023; 5(2): 89-100.

[29] Wang X, Huang X, Zhang Y. Involvement of human papillomaviruses in cervical cancer. Front Microbiol. 2018; 9: 2896.

[30] Hu S, Wu C, Wu X, et al. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities. Sci Bull. 2023; 68(23): 3003-3012.

[31] Du P, Wu C, Hu S, Fan R, Gao GF, Wang Q. The omicron BA.2.86 subvariant as a new serotype of SARS-CoV-2. Lancet Microbe. 2024; 5(6): e516.

[32] Qian W, Yicheng G, Anthony B, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. bioRxiv. 2023. 11.26.568730.

[33] Hu S, Wu C, Wu X, et al. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities. Sci Bull (Beijing). 2023; 68(23): 3003-3012.

[34] Wang Q, Guo Y, Bowen A, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024; 32(3): 315-321.e3.

[35] GISAID. Lineage Comparison. March 10, 2024. Accessed March 15, 2024. https://gisaid.org/lineage-comparison/

[36] Wang X, Lu L, Jiang S. SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences. Trends Immunol. 2024; 45(2): 81-84.

[37] Kamble P, Daulatabad V, Singhal A, et al. JN. 1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)? Hormone molecular biology and clinical investigation. Horm Mol Biol Clin Investig. 2024;45(2):49-53.

[38] Li W, Xu Z, Niu T, et al. Key mechanistic features of the trade-off between antibody escape and host cell binding in the SARS-CoV-2 Omicron variant spike proteins. EMBO J. 2024; 43(8): 1484-1498.

[39] Esmaeilzadeh A, Ebrahimi F, Jahani Maleki A, Siahmansouri A. EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19. Infection. 2024; 52(2): 337-343.

[40] Wang Q, Guo Y, Zhang RM, et al. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis. 2023; 23(10): e397-e398.

[41] Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21(3): 162-177.

[42] Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Antibody-mediated neutralization of SARS-CoV-2. Immunity. 2022; 55(6): 925-944.

[43] Kumar S, Chandele A, Sharma A. Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathog. 2021; 17(9): e1009885.

[44] Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023; 186(2): 279-286.e8.

[45] Nutalai R, Zhou D, Tuekprakhon A, et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell. 2022; 185(12): 2116-2131.e18.

[46] Yisimayi A, Song W, Wang J, et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature. 2024; 625(7993): 148-156.

[47] Cao Y, Jian F, Zhang Z, et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep. 2022; 41(12): 111845.

[48] Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020; 588(7839): 682-687.

[49] Li P, Faraone JN, Hsu CC, et al. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion. bioRxiv. 2024.

[50] Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815): 290-295.

[51] Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923): 593-602.

[52] Lustig Y, Gonen T, Meltzer L, et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat Immunol. 2022; 23(6): 940-946.

[53] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384(5): 403-416.

[54] Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection—increasing community access to testing program. MMWR Morb Mortal Wkly Rep. 2022; 71(48): 1526-1530.

[55] Chalkias S, McGhee N, Whatley JL, et al. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines. J Infect Dis. 2024:jiae067.

[56] Xun W, Shujun J, Wentai M, et al. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies. bioRxiv. 2024. 2024.02.16.580615.

[57] World Health Organization. Advice for the Public: Coronavirus Disease (COVID-19). WHO Diseases. March 18, 2023. Accessed February 25, 2024. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public

[58] Looi MK. Covid-19: WHO adds JN.1 as new variant of interest. BMJ. 2023; 383: 2975.

[59] Wahid M, Jawed A, Mandal RK, et al. Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update. Miner Med. 2023; 114(5): 683-697.

[60] Khan SA, Bhuiyan MA, Dewan SMR. JN.1: the present public health concern pertains to the emergence of a novel variant of COVID-19. Environ Health Insights. 2024; 18: 11786302241228958.

[61] Rathore APS, St John AL. Promises and challenges of mucosal COVID-19 vaccines. Vaccine. 2023; 41(27): 4042-4049.

[62] Reutovich AA, Srivastava AK, Arosio P, Bou-Abdallah F. Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development. Biochim Biophys Acta Gen Subj. 2023; 1867(3): 130288.

[63] Bonam SR, Hu H. Next-generation vaccines against COVID-19 variants: beyond the spike protein. Zoonoses (Burlingt). 2023; 3(1).

[64] Marks PW, Gruppuso PA, Adashi EY. Urgent need for next-generation COVID-19 vaccines. JAMA. 2023; 329(1): 19-20.

[65] Furlow B. Triple-demic overwhelms paediatric units in US hospitals. Lancet Child Adolesc Health. 2023; 7(2): 86.

[66] Mipatrini D, Montaldo C, Bartolini B, et al. Disease X’-time to act now and prepare for the next pandemic threat. Eur J Public Health. 2022; 32(6): 841-842.

[67] Arevalo-Romero JA, Chingaté-López SM, Camacho BA, Alméciga-Díaz CJ, Ramirez-Segura CA. Next-generation treatments: immunotherapy and advanced therapies for COVID-19. Heliyon. 2024; 10(5): e26423.

[68] Nobari S, Rezvan M, Dashtestani F, Gangi M, Keshmiri Neghab H. Cellular therapy: the hope for COVID-19. Avicenna J Med Biotechnol. 2022; 14(2): 104-113.

[69] Galván-Peña S, Leon J, Chowdhary K, et al. Profound Treg perturbations correlate with COVID-19 severity. Proc Natl Acad Sci U S A. 2021; 118(37): e2111315118.

[70] El Chaer F, Auletta JJ, Chemaly RF. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. Blood. 2022; 140(7): 673-684.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.